Both sorafenib and lenvatinib, used for HCC treatment, inhibit VEGFR-mediated signalling and carnitine transporters, which may suppress signalling in the downstream PI3k/Akt/mTOR pathway, leading to subsequent skeletal muscle mass loss [30]. This evidence concerns the gene KDR and hepatocellular carcinoma.